In today’s briefing:
- 2025 (“Year of the Snake”) Major IPOs Pipeline in Korea
- Sai Life Sciences Pre-IPO – Portfolio Expansion and Increased Production Capacity to Drive Growth
- A Review of Rights Offerings/Capital Raise Announcements in Korea in 2024
- ISU Petasys Ignores FSS: A Likely Short-Term Dip Sets up an Opportunity to Target 15% Discount
- DigiCo Infrastructure REIT IPO Trading – Now for the Real Test, Ex-Adjustments
- Inventurus Pre-IPO – Accelerating Growth with Major Aquity Acquisition
2025 (“Year of the Snake”) Major IPOs Pipeline in Korea
- This is our 10th “Annual Edition of the Major Korean IPOs Pipeline Preview” at Smartkarma.
- This insight will feature 50 of the biggest potential IPOs in Korea in 2025.
- These 50 IPOs in Korea are likely to represent more than 80% of all capital raised through IPOs in Korea next year.
Sai Life Sciences Pre-IPO – Portfolio Expansion and Increased Production Capacity to Drive Growth
- SAI Life Sciences (SAILS12 IN) is looking to raise up to US$360m in its upcoming India IPO.
- Sai Life Sciences is a contract research, development and manufacturing organisation providing end-to-end services across drug discovery, development and manufacturing value-chain, for small to global pharmaceutical innovators and biotechnology firms.
- In this note, we talk about the company’s historical performance.
A Review of Rights Offerings/Capital Raise Announcements in Korea in 2024
- In this insight, we review the major rights offerings/capital raises that were announced in Korea in 2024.
- In general, the major rights offerings/capital raises tend to result in lower share prices one month, three months, and over a longer time frame.
- There are some exceptions. Peptron and ABL Bio experienced higher share prices even after their capital raise announcements, especially after a longer time frame (3 months or more).
ISU Petasys Ignores FSS: A Likely Short-Term Dip Sets up an Opportunity to Target 15% Discount
- ISU Petasys is betting the FSS chief, tied to the current administration, won’t have much market power due to the impeachment drama—and that gamble looks likely to pay off.
- ISU Petasys’ rights offering still offers solid trade potential, with 97% stockholder allocation and only 21% from the major shareholder, increasing the chance of significant unclaimed shares hitting the market.
- Our plan is to grab stock rights cheap, ride the 15% discount, and capitalize on stock pullbacks, though lack of futures limits short hedging. Still, an unhedged setup looks promising.
DigiCo Infrastructure REIT IPO Trading – Now for the Real Test, Ex-Adjustments
- DigiCo REIT (DIGICO AU) raised around US$1.3bn in its Australian IPO.
- DigiCo REIT (DREIT) aims to be a diversified owner, operator and developer of data centres, with a global portfolio and broad investment mandate across stabilised, value-add and development opportunities
- We have looked at the company’s past performance in our previous notes. In this note, we will talk about the trading dynamics.
Inventurus Pre-IPO – Accelerating Growth with Major Aquity Acquisition
- Inventurus Knowledge Solutions (IKSINCD IN) is looking to raise up to US$295m in its upcoming India IPO.
- IKS is a technology-enabled healthcare solutions provider, assisting physician enterprises in US, Canada and Australia. It is a one-stop shop designed to handle physicians administrative tasks.
- In this note, we look at the firm’s past performance.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
